0000899243-21-013816.txt : 20210329 0000899243-21-013816.hdr.sgml : 20210329 20210329163534 ACCESSION NUMBER: 0000899243-21-013816 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210325 FILED AS OF DATE: 20210329 DATE AS OF CHANGE: 20210329 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Boudes Pol F CENTRAL INDEX KEY: 0001454771 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31791 FILM NUMBER: 21782140 MAIL ADDRESS: STREET 1: C/O CYMABAY THERAPEUTICS, INC. STREET 2: 7575 GATEWAY BLVD., SUITE 110 CITY: NEWARK STATE: CA ZIP: 94560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC CENTRAL INDEX KEY: 0001133416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043562325 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 BUSINESS PHONE: 678-620-3186 MAIL ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 FORMER COMPANY: FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010612 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-25 0 0001133416 GALECTIN THERAPEUTICS INC GALT 0001454771 Boudes Pol F C/O GALECTIN THERAPEUTICS INC. 4960 PEACHTREE INDUSTRIAL BLVD., STE240 NORCROSS GA 30071 0 1 0 0 Chief Medical Officer Stock option (right to buy) 2.11 2021-03-25 4 A 0 50000 0.00 A 2031-03-25 Common Stock 50000 50000 D Stock option (right to buy) 2.11 2021-03-25 4 A 0 100000 0.00 A 2031-03-25 Common Stock 100000 100000 D The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. Such options vest as follows: 25% on each on September 30, 2021, March 31, 2022, September 30, 2022 and March 31, 2023. Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results. /s/ Jack W. Callicutt, by power of attorney 2021-03-29